Published in Nature Neuroscience, the findings offer a promising route for developing new treatment options in Parkinson’s disease.
The annual event featured presentations by some of the leading scientists in the field, as well as a poster session showcasing recent research conducted by Feinberg faculty and staff.
Despite advances in neurosurgical techniques and radiation oncology, malignant brain tumors are the fourth most common cancer death in the United States. A recent publication by Northwestern Medicine scientists has revealed a potentially novel treatment option.
Circadian Science Advances Speed Up Importance Of Timing In Medicine
Published in PLOS ONE, the findings by a group of neurosurgeons could change the manner in which a fairly common lumbar procedure is performed in the future.
Young adults who used marijuana only recreationally showed significant abnormalities in two key brain regions that are important in emotion and motivation, scientists report.
The timing, intensity and duration of an individual’s light exposure during the day correlates to their body mass index.
Tanya Simuni, MD, was awarded a grant from the National Institutes of Health to conduct a $16 million phase III study of the safety and efficacy of the drug isradipine as a potential neuroprotective agent in Parkinson’s disease.
M. Marsel Mesulam, MD, director of the Cognitive Neurology and Alzheimer’s Disease Center, will travel to Philadelphia at the end of April to be honored at the annual American Academy of Neurology meeting.
Developed by Gregory Dumanian, MD, and Todd A Kuiken, MD, PhD, targeted muscle reinnervation enables an amputee to control motorized prosthetic devices and regain sensory feedback. New research also shows that it reduces neuroma pain from cut nerve endings.